NCI DCP needs your feedback, comments, innovative ideas, and strategies to guide efforts in expanding and improving the development of the molecular cancer prevention and cancer interception research workforce. This includes education and training needs for both early-career (e.g., pre- and postdoctoral fellows, early-stage investigators) and mid-career scientists who are passionate about cancer prevention or may be seeking to enter the fields of molecular cancer prevention and cancer interception (including foundational/basic, translational, and clinical research), as well as specific research areas within these fields. NCI also seeks input on how to best support successful career transitions for molecular cancer prevention and cancer interception scientists to enable these scientists to become leaders in the broader cancer prevention research community, and across various career sectors (i.e., academia, industry, and government). Reply via web form by June 30.

HEAL Initiative Partnerships to Advance Interdisciplinary (PAIN) Training in Clinical Pain Research: The HEAL PAIN Cohort Program (T90/R90): Applications Due September 26

To bolster the dwindling clinical pain research workforce, the HEAL PAIN Cohort Program will support interdisciplinary postdoctoral training to promote the next generation of independent clinical pain researchers. The HEAL PAIN Cohort Program will fund up to four T90/R90 institutional postdoctoral training programs in clinical pain research and foster a cohort experience among programs at different institutions through the HEAL R24 Coordinating Center for National Pain Scientists.

HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3): Applications Due October 24

The purpose of this Notice of Funding Opportunity is to promote the discovery of candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials. The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics.

For more information on these NOFOs, please contact Rachel Altshuler, Ph.D.

An estimated 153,020 men and women in the U.S. will be diagnosed with colorectal cancer in 2023, and 52,550 are expected to die of this disease. In two recent studies, researchers addressed the impact of overweight, obesity, and body mass index (BMI) on colorectal and non-colorectal gastrointestinal (GI) cancers at different stages of adult life, as well as the association of BMI and different molecular subtypes in colorectal cancers.

Read the blog